Rs Crum Inc. Inhibrx, Inc. Transaction History

Rs Crum Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$32.76 - $39.56 $17,690 - $21,362	-540 Reduced 3.68%	14,119 $493,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $169,751 - $362,517	14,659 New	14,659 $263,000
Q2 2022 Jul 27, 2022	SELL	$8.52 - $25.26 $124,894 - $370,286	-14,659 Closed	0 $0
Q1 2022 Apr 21, 2022	BUY	$19.89 - $43.18 $291,567 - $632,975	14,659 New	14,659 $327,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Rs Crum Inc., based on Form 13F filings with the SEC.

Stay updated on Rs Crum Inc. with notifications on news.